Kyverna Therapeutics (NASDAQ:KYTX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Kyverna Therapeutics (NASDAQ:KYTX) from a sell rating to a hold rating in a report released on Sunday morning.

A number of other equities research analysts also recently commented on the stock. Morgan Stanley set a $33.00 price objective on shares of Kyverna Therapeutics in a research report on Monday, December 15th. Wells Fargo & Company raised their price target on Kyverna Therapeutics from $31.00 to $33.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Monday, December 29th. Finally, HC Wainwright raised their target price on Kyverna Therapeutics from $10.00 to $20.00 and gave the stock a “buy” rating in a research report on Monday, October 27th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $28.67.

Kyverna Therapeutics Stock Up 5.2%

NASDAQ:KYTX opened at $8.66 on Friday. Kyverna Therapeutics has a 52 week low of $1.78 and a 52 week high of $13.67. The company has a fifty day simple moving average of $7.99 and a two-hundred day simple moving average of $5.87. The company has a market cap of $379.31 million, a price-to-earnings ratio of -2.32 and a beta of 3.45.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.12. On average, analysts expect that Kyverna Therapeutics will post -3.29 EPS for the current year.

Insider Buying and Selling

In other news, Director Beth C. Seidenberg purchased 133,333 shares of the company’s stock in a transaction dated Thursday, December 18th. The shares were acquired at an average cost of $7.50 per share, for a total transaction of $999,997.50. Following the completion of the purchase, the director directly owned 869,317 shares in the company, valued at $6,519,877.50. The trade was a 18.12% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CTO Karen Marie Walker sold 23,998 shares of Kyverna Therapeutics stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $12.20, for a total value of $292,775.60. Following the completion of the sale, the chief technology officer owned 22,636 shares in the company, valued at approximately $276,159.20. This trade represents a 51.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure.

Institutional Trading of Kyverna Therapeutics

Several institutional investors have recently made changes to their positions in the stock. TD Asset Management Inc raised its stake in shares of Kyverna Therapeutics by 179.5% in the 2nd quarter. TD Asset Management Inc now owns 252,196 shares of the company’s stock valued at $774,000 after purchasing an additional 161,954 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in Kyverna Therapeutics during the second quarter valued at approximately $129,000. Ethic Inc. bought a new position in Kyverna Therapeutics during the 2nd quarter worth approximately $56,000. Phoenix Wealth Advisors acquired a new position in shares of Kyverna Therapeutics in the 2nd quarter worth approximately $32,000. Finally, Catalyst Funds Management Pty Ltd bought a new stake in shares of Kyverna Therapeutics in the 2nd quarter valued at approximately $37,000. 18.08% of the stock is owned by hedge funds and other institutional investors.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical?stage biotechnology company dedicated to developing engineered regulatory T?cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen?specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.